Publications

@article{Panos2023-mp,

title = {Faricimab: Transforming the future of macular diseases treatment 

 - A comprehensive review of clinical studies},

author = {Georgios D Panos and Arun Lakshmanan and Panagiotis Dadoukis and Matteo Ripa and Lorenzo Motta and Winfried M Amoaku},

year  = {2023},

date = {2023-09-01},

journal = {Drug Des. Devel. Ther.},

volume = {17},

pages = {2861\textendash2873},

publisher = {Informa UK Limited},

abstract = {Degenerative eye conditions such as age-related macular 

 degeneration (AMD), diabetic retinopathy, and retinal vein 

 occlusion are major contributors to significant vision loss in 

 developed nations. The primary therapeutic approach for managing 

 complications linked to these diseases involves the intravitreal 

 delivery of anti-vascular endothelial growth factor (VEGF) 

 treatments. Faricimab is a novel, humanised, bispecific antibody 

 that simultaneously binds all VEGF-A isoforms and 

 Angiopoietin-2, which has been approved by regulatory agencies, 

 such as the US Food and Drug Administration (FDA), the UK 

 Medicines and Healthcare products Regulatory Agency (MHRA) and 

 the European Medicines Agency (EMA), for the treatment of 

 neovascular AMD and diabetic macular oedema (DMO). Intravitreal 

 faricimab holds the promise of reducing the treatment burden for 

 patients with these conditions by achieving comparable or 

 superior therapeutic outcomes with fewer clinic visits. The 

 scope of faricimab's application includes addressing complex 

 macular conditions such as DMO. This review intends to elucidate 

 the distinctive pharmacological characteristics of faricimab and 

 provide an overview of the key clinical trials and real-world 

 studies that assess its effectiveness and safety in treating 

 degenerative macular diseases.},

keywords = {age-related macular degeneration, anti-VEGF, degenerative   macular disorders, diabetic   retinopathy, diabetic macular oedema, efficacy, faricimab, intravitreal treatment, retinal vein occlusion, safety},

pubstate = {published},

tppubtype = {article}

}

@article{Fung2022-uv,

title = {Diabetic retinopathy for the non-ophthalmologist},

author = {Timothy Hm Fung and Bakula Patel and Emma G Wilmot and Winfried Mk Amoaku},

year  = {2022},

date = {2022-03-01},

journal = {Clin. Med.},

volume = {22},

number = {2},

pages = {112\textendash116},

publisher = {Elsevier BV},

abstract = {Diabetic retinopathy is a microangiopathy resulting from the 

 chronic effects of diabetes mellitus. Healthcare professionals 

 often work in isolation to deliver highly specialised care 

 efficiently and effectively for people living with diabetes. It 

 is not uncommon for people with diabetes to be making frequent 

 visits to community and hospital clinics to see a variety of 

 specialists and healthcare professionals, with seemingly little 

 opportunity for coordination of this complex health management 

 programme between the wider team. In a field that is so diverse 

 and rapidly changing, healthcare professionals of all 

 specialties need to be aware of developments across all aspects 

 of diabetes management. In this article, we discuss the 

 epidemiology and natural history of diabetic retinopathy and 

 describe an approach to its assessment and diagnosis. We provide 

 an overview of the principles of diabetic retinopathy management 

 and outline possible future treatments for diabetic retinopathy.},

keywords = {diabetic macular oedema, diabetic retinopathy, intravitreal   injections, laser photocoagulation, vitrectomy},

pubstate = {published},

tppubtype = {article}

}